Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | PPIA | P62937 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2237686 | 0.92 | ALDH1A1 (0.49) | HPGDALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL2240565 | 0.85 | HPGD (0.44) | HPGDALDH1A1GAAMEN1KMT2A | |
| SCHEMBL19709882 | 0.84 | MAOB (0.48) | HPGDALDH1A1MAOBMEN1KMT2A | |
| SCHEMBL19646278 | 0.84 | ALDH1A1 (0.43) | KDM4EHPGDALDH1A1GLAGAA | |
| SCHEMBL16789591 | 0.83 | GLRA1 (0.47) | HPGDALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL6865199 | 0.81 | HPGD (0.38) | HPGDALDH1A1GAAMEN1KMT2A | |
| SCHEMBL757286 | 0.80 | TSHR (0.46) | KDM4EHPGDALDH1A1GLAGAA | |
| SCHEMBL6858810 | 0.80 | LIPG (0.47) | KDM4EHPGDALDH1A1GLAGAA | |
| SCHEMBL8333370 | 0.78 | LIPG (0.47) | KDM4EHPGDALDH1A1GLAGAA | |
| SCHEMBL28877532 | 0.78 | ALDH1A1 (0.56) | HPGDALDH1A1MAOBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220143229-A1 | RADIO-PHARMACEUTICAL COMPLEXES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-05-12 | — | — | US | disclosed |
| US-20220143229-A1 | RADIO-PHARMACEUTICAL COMPLEXES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-05-12 | — | — | US | disclosed |
| US-11260136-B2 | Radio-pharmaceutical complexes | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-03-01 | — | — | US | disclosed |
| US-20210322583-A1 | RADIO-PHARMACEUTICAL COMPLEXES | BAYER AS (NO) | 2021-10-21 | — | — | US | disclosed |
| US-20210322583-A1 | RADIO-PHARMACEUTICAL COMPLEXES | BAYER AS (NO) | 2021-10-21 | — | — | US | disclosed |
| CN-107278155-B | Radiopharmaceutical complexes | 拜耳有限公司 | 2021-03-30 | — | — | CN | disclosed |
| US-20190298865-A1 | RADIO-PHARMACEUTICAL COMPLEXES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-03 | — | — | US | disclosed |
| US-20190298865-A1 | RADIO-PHARMACEUTICAL COMPLEXES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-03 | — | — | US | disclosed |
| EP-3468619-A1 | RADIO-PHARMACEUTICAL COMPLEXES | Bayer Pharma Aktiengesellschaft (DE) | 2019-04-17 | — | — | EP | disclosed |
| US-20190091354-A1 | RADIO-PHARMACEUTICAL COMPLEXES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-03-28 | — | — | US | disclosed |
| WO-2017211809-A1 | RADIO-PHARMACEUTICAL COMPLEXES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017211809-A1 | RADIO-PHARMACEUTICAL COMPLEXES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-12-14 | — | — | WO | disclosed |
| US-20170340759-A1 | RADIO-PHARMACEUTICAL COMPLEXES | BAYER AS (NO) | 2017-11-30 | — | — | US | disclosed |
| US-20170340759-A1 | RADIO-PHARMACEUTICAL COMPLEXES | BAYER AS (NO) | 2017-11-30 | — | — | US | disclosed |
| US-20170340759-A1 | RADIO-PHARMACEUTICAL COMPLEXES | BAYER AS (NO) | 2017-11-30 | — | — | US | disclosed |
| EP-3233137-A1 | RADIO-PHARMACEUTICAL COMPLEXES | Bayer AS (NO) | 2017-10-25 | — | — | EP | disclosed |
| WO-2017162555-A1 | RADIO-PHARMACEUTICAL COMPLEXES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017162555-A1 | RADIO-PHARMACEUTICAL COMPLEXES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-28 | — | — | WO | disclosed |
| WO-2016096843-A1 | RADIO-PHARMACEUTICAL COMPLEXES | BAYER AS (NO) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016096843-A1 | RADIO-PHARMACEUTICAL COMPLEXES | BAYER AS (NO) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210322583-A1 | RADIO-PHARMACEUTICAL COMPLEXES | PTMS, THOP1, PHPT1 | KDM4E 4009/4885HPGD 1440/4885ALDH1A1 3512/4885 |
| US-20220143229-A1 | RADIO-PHARMACEUTICAL COMPLEXES | EGFR, MET, ERBB2 | KDM4E 1959/4885HPGD 608/4885ALDH1A1 3506/4885 |
| US-11260136-B2 | Radio-pharmaceutical complexes | EGFR, MET, ERBB2 | KDM4E 2112/4885HPGD 531/4885ALDH1A1 3148/4885 |
| US-20170340759-A1 | RADIO-PHARMACEUTICAL COMPLEXES | PTMS, THOP1, PHPT1 | KDM4E 4022/4885HPGD 1420/4885ALDH1A1 3524/4885 |
| US-20190091354-A1 | RADIO-PHARMACEUTICAL COMPLEXES | EGFR, MET, ERBB2 | KDM4E 2143/4885HPGD 544/4885ALDH1A1 3158/4885 |
| US-20190298865-A1 | RADIO-PHARMACEUTICAL COMPLEXES | FAP, PHPT1, DNPEP | KDM4E 1459/4885HPGD 632/4885ALDH1A1 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.